GSK Bets Up to $750 Million on Chimagen Blood Cancer Therapy to Deepen Its Oncology Push

GSK (GSK) moved decisively to strengthen its blood-cancer franchise on Tuesday, agreeing to acquire global rights to an experimental multiple myeloma therapy from Chinese biotech Chimagen Biosciences in a deal worth up to $750 million. Specifically, the UK drugmaker will take control of Chimagen’s trispecific T-cell engager program, pay an upfront fee, and then layer on milestone payments as the asset advances through development and commercialization.

Key Points

• GSK (GSK) is paying up to $750 million — an upfront fee plus success-based development and commercial milestones — for global rights to Chimagen’s trispecific T-cell engager for multiple myeloma.
• Phase 1 trials are slated to begin next year, targeting the third most common form of blood cancer.
• The therapy aims to solve a key problem: it’s engineered to improve the poor tolerability that typically limits T-cell engager drugs, potentially enabling wider and earlier use.
• The market opportunity is large. GSK cites forecasts that the U.S. T-cell engager market for multiple myeloma could exceed $10 billion by 2032.
• Analysts cheered the move. Berenberg upgraded GSK to buy from hold, pointing to accelerating pipeline momentum.
• This extends a broader oncology M&A wave that also includes Merck (MRK) and Eli Lilly (LLY).

Inside the Deal

Under the agreement, GSK (GSK) will pay Chimagen an upfront sum to secure full global rights to the program and then add development and commercial milestone payments as the therapy hits specific targets. From there, GSK plans to develop and commercialize the asset itself, with Phase 1 trials expected to start next year.

Crucially, the therapy targets multiple myeloma, the third most common blood cancer. Moreover, Chimagen designed the drug specifically to overcome the difficult tolerability profiles that usually hold back T-cell engager therapies — a feature that, according to GSK, could open the door to broader adoption and earlier use in treatment.

“Today’s deal secures a promising T cell engager and advances GSK’s leadership goals in blood cancer,” said Hesham Abdullah, GSK’s global head of oncology R&D, adding that it complements the company’s existing multiple myeloma portfolio. Meanwhile, Chimagen CEO Zhenhao Zhou framed the partnership as a way to pair his company’s precision program with GSK’s global development and commercial reach.

Why It Matters

GSK isn’t buying blind here. Rather, it’s deepening an existing relationship: back in 2024, the company acquired Chimagen’s CMG1A46 candidate for $300 million upfront and up to $550 million in milestones, and that asset is now in Phase 1 studies for B-cell malignancies and autoimmune disorders. Consequently, this second deal builds on a partnership GSK already knows well.

The financial upside also looks compelling. Because GSK cites forecasts that the U.S. T-cell engager market for multiple myeloma could surpass $10 billion by 2032, the company is positioning itself early in a rapidly expanding treatment category.

The Analyst Take

Wall Street responded favorably. Berenberg upgraded GSK to buy from hold, telling clients it has grown “increasingly optimistic” about the drugmaker’s growth outlook amid a wave of business development. Notably, the brokerage pointed out that 10 of GSK’s 11 novel Phase 3 assets come from external sources, and six of those could each generate at least £2 billion ($2.7 billion) in sales. As analyst Kerry Holford’s team put it, they “support this allocation of capital and much needed pipeline supplementation.”

The Bigger Picture

This transaction fits a clear industry pattern rather than standing alone. Earlier this year, GSK (GSK) completed its $10.6 billion acquisition of Nuvalent, adding three lung-cancer assets, and in 2022 it bought Sierra Oncology for rare-cancer therapies. Meanwhile, rivals have chased similar deals: Merck (MRK) acquired Terns Pharmaceuticals for $6.7 billion in May, and Eli Lilly (LLY) agreed to buy Kelonia Therapeutics for up to $7 billion in April. Taken together, these moves underscore how aggressively big pharma keeps buying its way into next-generation oncology.